{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T15:29:59Z","timestamp":1759073399457,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T00:00:00Z","timestamp":1481241600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T00:00:00Z","timestamp":1481241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HHSN275201000003I","K23HD083465"],"award-info":[{"award-number":["HHSN275201000003I","K23HD083465"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001117"],"award-info":[{"award-number":["UL1TR001117"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01-HD076676-01A1"],"award-info":[{"award-number":["1R01-HD076676-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201500006I","HHSN272201300017I"],"award-info":[{"award-number":["HHSN272201500006I","HHSN272201300017I"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["1U01FD004858-01"],"award-info":[{"award-number":["1U01FD004858-01"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"crossref","award":["HHSO100201300009C"],"award-info":[{"award-number":["HHSO100201300009C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23NS085049"],"award-info":[{"award-number":["K23NS085049"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40262-016-0486-0","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T12:11:41Z","timestamp":1481285501000},"page":"941-951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Population Pharmacokinetics and Exploratory Pharmacodynamics of Lorazepam in Pediatric Status Epilepticus"],"prefix":"10.1007","volume":"56","author":[{"name":"On behalf of the Best Pharmaceuticals for Children Act \u2013 Pediatric Trials Network Steering Committee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey T.","family":"Guptill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barrie","family":"Harper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund V.","family":"Capparelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,9]]},"reference":[{"key":"486_CR1","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s12028-013-9935-x","volume":"20","author":"BS Dham","year":"2014","unstructured":"Dham BS, Hunter K, Rincon F. The epidemiology of status epilepticus in the United States. Neurocrit Care. 2014;20:476\u201383.","journal-title":"Neurocrit Care."},{"key":"486_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(06)69043-0","volume":"368","author":"RFM Chin","year":"2006","unstructured":"Chin RFM, Neville BGR, Peckham C, Bedford H, Wade A, Scott RC. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet. 2006;368:222\u20139.","journal-title":"Lancet."},{"key":"486_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","volume":"14","author":"JP Betjemann","year":"2015","unstructured":"Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14:615\u201324.","journal-title":"Lancet Neurol."},{"key":"486_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11910-009-0022-9","volume":"9","author":"R Singh","year":"2009","unstructured":"Singh R, Gaillard W. Status epilepticus in children. Curr Neurol Neurosci Rep. 2009;9:137\u201344.","journal-title":"Curr Neurol Neurosci Rep."},{"key":"486_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","volume":"16","author":"T Glauser","year":"2016","unstructured":"Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16:48\u201361.","journal-title":"Epilepsy Curr."},{"key":"486_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","volume":"17","author":"GM Brophy","year":"2012","unstructured":"Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3\u201323.","journal-title":"Neurocrit Care."},{"key":"486_CR7","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1001\/jama.2014.2625","volume":"311","author":"JM Chamberlain","year":"2014","unstructured":"Chamberlain JM, Okada P, Holsti M, Mahajan P, Brown KM, Vance C, et al. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA. 2014;311:1652\u201360.","journal-title":"JAMA."},{"key":"486_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/jps.2600680119","volume":"68","author":"DJ Greenblatt","year":"1979","unstructured":"Greenblatt DJ, Shader RI, Franke K, MacLaughlin DS, Harmatz JS, Allen MD, et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci. 1979;68:57\u201363.","journal-title":"J Pharm Sci."},{"key":"486_CR9","unstructured":"Watson Laboratories, Inc. Lorazepam injection package insert. Available at: http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=ae274b1f-27c3-483b-99f1-9a9249dc2459 . Accessed 12 Feb 2016."},{"key":"486_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1124\/dmd.113.051656","volume":"41","author":"V Uchaipichat","year":"2013","unstructured":"Uchaipichat V, Suthisisang C, Miners JO. The glucuronidation of R- and S-lorazepam: Human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs. Drug Metab Dispos. 2013;41:1273\u201384.","journal-title":"Drug Metab Dispos."},{"key":"486_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0022-3476(05)80925-4","volume":"120","author":"C McDermott","year":"1992","unstructured":"McDermott C, Kowalczyk A, Schnitzler E, Mangurten H, Rodvold K, Metrick S. Pharmacokinetics of lorazepam in critically ill neonates with seizures. J Pediatr. 1992;120:479\u201383.","journal-title":"J Pediatr."},{"key":"486_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/clpt.1991.117","volume":"50","author":"WR Crom","year":"1991","unstructured":"Crom WR, Relling MV, Christensen ML, Rivera GK, Evans WE. Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. Clin Pharmacol Ther. 1991;50:132\u201340.","journal-title":"Clin Pharmacol Ther."},{"issue":"667\u201372","key":"486_CR13","first-page":"e2","volume":"160","author":"JM Chamberlain","year":"2012","unstructured":"Chamberlain JM, Capparelli EV, Brown KM, Vance CW, Lillis K, Mahajan P, et al. Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. J Pediatr. 2012;160(667\u201372):e2.","journal-title":"J Pediatr."},{"key":"486_CR14","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D. Multicompartment models. In: Gibaldi M, Perrier D, editors. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.","edition":"2"},{"key":"486_CR15","doi-asserted-by":"crossref","unstructured":"Barr J, Zomorodi K, Bertaccini EJ, Shafer SL, Geller E. A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. Anesthesiology. 2001;95:286\u201398.","DOI":"10.1097\/00000542-200108000-00007"},{"key":"486_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1528-1157.1984.tb03444.x","volume":"25","author":"JE Walker","year":"1984","unstructured":"Walker JE, Homan RW, Crawford IL. Lorazepam: a controlled trial in patients with intractable partial complex seizures. Epilepsia. 1984;25:464\u20136.","journal-title":"Epilepsia."},{"key":"486_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0022-3476(89)80713-9","volume":"114","author":"MV Relling","year":"1989","unstructured":"Relling MV, Mulhern RK, Dodge RK, Johnson D, Pieper JA, Rivera GK, et al. Lorazepam pharmacodynamics and pharmacokinetics in children. J Pediatr. 1989;114:641\u20136.","journal-title":"J Pediatr."},{"key":"486_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1046\/j.1365-2125.2003.01957.x","volume":"57","author":"EL Swart","year":"2003","unstructured":"Swart EL, Zuideveld KP, De Jongh J, Danhof M, Thijs LG, Strack van Schijndel RMJ. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol. 2003;57:135\u201345.","journal-title":"Br J Clin Pharmacol."},{"key":"486_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/gut.50.2.259","volume":"50","author":"CP Strassburg","year":"2002","unstructured":"Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut. 2002;50:259\u201365.","journal-title":"Gut."},{"key":"486_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/toxsci\/kfu126","volume":"141","author":"K Divakaran","year":"2014","unstructured":"Divakaran K, Hines RN, McCarver DG. Human hepatic UGT2B15 developmental expression. Toxicol Sci. 2014;141:292\u20139.","journal-title":"Toxicol Sci."},{"key":"486_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/bja\/aeh042","volume":"92","author":"NJ Bouwmeester","year":"2004","unstructured":"Bouwmeester NJ. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth. 2004;92:208\u201317.","journal-title":"Br J Anaesth."},{"key":"486_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2125.2007.02966.x","volume":"65","author":"SN Muchohi","year":"2008","unstructured":"Muchohi SN, Kokwaro GO, Ogutu BR, Edwards G, Ward SA, Newton CRJC. Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions. Br J Clin Pharmacol. 2008;65:12\u201321.","journal-title":"Br J Clin Pharmacol."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0486-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0486-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0486-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T19:30:49Z","timestamp":1657999849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0486-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,9]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["486"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0486-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2016,12,9]]},"assertion":[{"value":"9 December 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was funded under National Institute of Child Health and Human Development (NICHD) contract HHSN275201000003I (principal investigator: Benjamin) for the Pediatric Trials Network. Research reported in this publication was also supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) under award number UL1TR001117.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Daniel Gonzalez receives research support from the NICHD (K23HD083465), the non-profit organization Thrasher Research Fund (), and from industry (Cempra, Inc. and Jacobus Pharmaceutical Company, Inc.) for drug development in adults and children. Michael Cohen-Wolkowiez receives research support from the NIH (1R01-HD076676-01A1), National Center for Advancing Translational Sciences of the NIH (UL1TR001117), National Institute of Allergy and Infectious Disease (NIAID; HHSN272201500006I and HHSN272201300017I), NICHD (HHSN275201000003I), FDA (1U01FD004858-01), Biomedical Advanced Research and Development Authority (BARDA; HHSO100201300009C), and the non-profit organization Thrasher Research Fund () for drug development in adults and children (). Jeffrey T. Guptill receives research support through K23NS085049 from the National Institute of Neurological Disorders and Stroke (NINDS). James M. Chamberlain, Barrie Harper, Jian Zhao, and Edmund V. Capparelli have no conflicts of interest to disclose.The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Both pediatric studies were reviewed and approved by local Institutional Review Boards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"For the Status\u00a01 study, patients either pre-consented to participate in the study prior to the presentation of SE or consented to participate in the study after they received lorazepam if they presented to the Emergency Department with SE. For the Status\u00a02 study, participating hospitals submitted a site-specific plan to their Institutional Review Board regarding the specific activities to address the requirements for the Exception from Informed Consent for Emergency Research (21 CFR 50.24). Thus, patients were treated prior to consent and then once their condition had stabilized the family was approached to discuss the study and obtain written consent for continued study participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}